PMID- 8263817
OWN - NLM
STAT- MEDLINE
DCOM- 19940127
LR  - 20131121
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 267
IP  - 3
DP  - 1993 Dec
TI  - Tumor necrosis factor-alpha mediates endotoxin-induced lung injury in platelet 
      activating factor-primed rats.
PG  - 1550-7
AB  - We have reported recently that lipopolysaccharide endotoxin and platelet 
      activating factor cooperate in priming relationships to elicit lung microvascular 
      injury. Lung injury was associated with elevated serum levels of tumor necrosis 
      factor-alpha (TNF alpha) and histological findings highly reminiscent of the 
      adult respiratory distress syndrome. The present study was designed to examine 
      the role of TNF alpha in lipopolysaccharide/platelet activating factor-induced 
      lung injury by utilizing a highly specific monoclonal antibody which block TNF 
      alpha actions (anti-TNF alpha monoclonal antibody). Pretreatment with anti-TNF 
      alpha monoclonal antibody (2.5-25 mg/kg i.v., n = 5-9) dose-dependently prevented 
      the lipopolysaccharide/platelet activating factor-induced histopathological 
      changes, lung edema (P < .01), lung myeloperoxidase activity (P < .01), elevation 
      of neutrophil count in bronchoalveolar lavage fluid (P < .01) and increased serum 
      thromboxane B2 (P < .01). Indomethacin (6 mg/kg i.v., n = 5) failed to modify the 
      lung injury despite complete inhibition of thromboxane B2 formation (P < .05). 
      These data suggest that TNF alpha might play a key role in initiation of the 
      early inflammatory changes which lead to adult respiratory distress syndrome.
FAU - Rabinovici, R
AU  - Rabinovici R
AD  - Department of Surgery, Jefferson Medical College, Philadelphia, Pennsylvania.
FAU - Bugelski, P J
AU  - Bugelski PJ
FAU - Esser, K M
AU  - Esser KM
FAU - Hillegass, L M
AU  - Hillegass LM
FAU - Griswold, D E
AU  - Griswold DE
FAU - Vernick, J
AU  - Vernick J
FAU - Feuerstein, G
AU  - Feuerstein G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Platelet Activating Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 57576-52-0 (Thromboxane A2)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/pharmacology
MH  - Bronchoalveolar Lavage Fluid/cytology
MH  - Capillary Permeability/drug effects
MH  - Cricetinae
MH  - Indomethacin/pharmacology
MH  - Leukocyte Count
MH  - Leukocytes/cytology
MH  - *Lipopolysaccharides
MH  - Lung/anatomy & histology/blood supply/enzymology
MH  - Lung Diseases/*blood/*chemically induced/pathology
MH  - Male
MH  - Organ Size/drug effects
MH  - Peroxidase/metabolism
MH  - *Platelet Activating Factor
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Thromboxane A2/biosynthesis/blood/*physiology
MH  - Time Factors
MH  - Tumor Necrosis Factor-alpha/immunology/metabolism/*physiology
EDAT- 1993/12/01 00:00
MHDA- 1993/12/01 00:01
CRDT- 1993/12/01 00:00
PHST- 1993/12/01 00:00 [pubmed]
PHST- 1993/12/01 00:01 [medline]
PHST- 1993/12/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1993 Dec;267(3):1550-7.